The Latest Breaking News from VKTX

Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.

Stocks gained after the Fed meeting but drifted lower after disappointing guidance from FedEx; next week's inflation data is unlikely to provide needed clarity

Stocks tried to stage a weak rally to close the week but the short-term outlook will continue to be dictated by the uncertainty that is creating volatility

Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

With weight-loss drugs gaining traction, which biopharma stock wins?

Rising costs, regulatory hurdles, and cyberattacks are some of the challenges that the pharmaceutical industry faces. Although the sector looks well-positioned for growth, not all pharma stocks would be able to capitalize on the industry trends. Therefore, investors should look to avoid fundamentally weak pharma stocks: Madrigal Pharmaceuticals (MDGL), Viking…

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?